EFFECT OF ANTI-PCSK9 ANTIBODIES ON ARTERY STRUCTURE AND FUNCTION: THE NIGUARDA HOSPITAL COHORT
Anno:
2024
Background: PCSK9 inhibitors antibodies (PCSK9-i) are a valid option to reduce LDL cholesterol in patients who failed to reach therapeutic target with maximized lipid-lowering therapies or in patient with statins intolerances. These antibodies reduce the frequency of new cardiovascular events, however if this effect is due only to LDL…